Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease

References

• Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009;136:1182–97.
   PubMed Web of Science ®Google Scholar
• Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008:CD006893.
   Google Scholar
• Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006:CD005112.
   Web of Science ®Google Scholar
• European Medicines Agency (EMEA). European Public Assessment Report (EPAR) for Remicade. Available at: www.emeaeuropa.eu/humandocs/PDFs/EPAR/Remicade/H-240-PI-en pdf.
   Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541–9.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323–33.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56:1232–9.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52–65.
   PubMed Web of Science ®Google Scholar
• Clark M, Colombel JF, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA, American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21–23, 2006. Gastroenterology 2007;133:312–39.
   PubMed Web of Science ®Google Scholar
• Bendtzen K, Ainsworth M, Steenholdt C, Thomsen OO, Brynskov J. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol 2009;44:774–81.
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601–8.
   PubMed Web of Science ®Google Scholar
• Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003;124:917–24.
   PubMed Web of Science ®Google Scholar
• Ternant D, Aubourg A, Magdelaine-Beuzelin C, Degenne D, Watier H, Picon L, Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 2008;30:523–9.
   PubMed Web of Science ®Google Scholar
• Candon S, Mosca A, Ruemmele F, Goulet O, Chatenoud L, Cezard JP. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. Clin Immunol 2006;118:11–19.
   PubMed Web of Science ®Google Scholar
• Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1248–54.
   PubMed Web of Science ®Google Scholar
• Van AG, Magdelaine-Beuzelin C, D'Haens G, Baert F, Noman M, Vermeire S, Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008;134:1861–8.
   PubMedGoogle Scholar
• Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010;59:49–54.
   PubMed Web of Science ®Google Scholar
• Cornillie F, Shealy D, D'Haens G, Geboes K, Van Assche G, Ceuppens J, Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 2001;15:463–73.
   PubMed Web of Science ®Google Scholar
• Afif W, Loftus EV Jr, Faubion WA, Kane SV, Bruining DH, Hanson KA, Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105(5):1140–1.
   PubMedGoogle Scholar
• Munkholm P, Langholz E, Nielsen OH, Kreiner S, Binder V. Incidence and prevalence of Crohn's disease in the county of Copenhagen, 1962–87: a sixfold increase in incidence. Scand J Gastroenterol 1992;27:609–14.
   PubMed Web of Science ®Google Scholar
• Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994;107:3–11.
   PubMed Web of Science ®Google Scholar
• Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008;103:944–8.
   PubMed Web of Science ®Google Scholar
• Biomonitor A/S, Copenhagen, Denmark. Available at: www.biomonitor.dk.
   Google Scholar
• Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006;54:3782–9.
   PubMed Web of Science ®Google Scholar
• Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology 2007;46:1828–34.
   PubMed Web of Science ®Google Scholar
• Arnese M, Salustri A, Fioretti PM, Cornel JH, Boersma E, Reijs AE, Quantitative angiographic measurements of isolated left anterior descending coronary artery stenosis. Correlation with exercise echocardiography and technetium-99 m 2-methoxy isobutyl isonitrile single-photon emission computed tomography. J Am Coll Cardiol 1995;25:1486–91.
   PubMedGoogle Scholar
• Available at: https://faculty.vassar.edu/lowry/clin1.html. 2010.
   Google Scholar
• Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876–85.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004;2:542–53.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007;56:1226–31.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402–13.
   PubMed Web of Science ®Google Scholar
• Bendtzen K, Steenholdt C, Ainsworth M, Thomsen OO, Brynskov J. Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factor-alpha inhibitors. Ugeskr Laeger 2010;172:44–7.
   PubMedGoogle Scholar
• Hennig C, Rink L, Fagin U, Jabs WJ, Kirchner H. The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs. J Immunol Methods 2000;235:71–80.
   PubMed Web of Science ®Google Scholar
• Bendtzen K. Anti-IFN BAb and NAb antibodies: a minireview. Neurology 2003;61(9 Suppl 5):S6–10.
   Google Scholar
• Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis 2009;15:1264–75.
   PubMed Web of Science ®Google Scholar
• Bendtzen K, Steenholdt C, Ainsworth M, Thomsen OO, Brynskov J. Comment on ‘Predicting the response to infliximab from trough serum levels’. Gut 2010;59:1298–9.
   PubMedGoogle Scholar
• Aarden L, Ruuls SR, Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol 2008;20:431–5.
   PubMed Web of Science ®Google Scholar
• Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009;68:1739–45.
   PubMed Web of Science ®Google Scholar